BIO-TECHNE executive reports initial share and award holdings
BIO-TECHNE Corp executive Steven C. Crouse, President – Diagnostics & Spatial Biology, filed an initial Form 3 reporting his equity holdings.
Rhea-AI Filing Summary
BIO-TECHNE Corp executive Steven C. Crouse, President – Diagnostics & Spatial Biology, filed an initial Form 3 reporting his equity holdings. He directly holds restricted stock units, stock options and common stock, including 6,529 restricted stock units and 5,894 shares of common stock.
The footnotes explain that each restricted stock unit represents a right to receive one share of Bio-Techne common stock, with multiple RSU and option grants vesting in scheduled installments between 2025 and 2029. The filing does not show any new share purchases or sales, only existing awards and their vesting timelines.
Positive
- None.
Negative
- None.
Insider Trade Summary
14 transactions reported
Mixed
14 txns
Insider
Crouse Steven C.
Role
President - Diag & Spatial Bi
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 15,033 contracts (Direct);
Stock Option (right to buy) — 109,142 contracts (Direct);
Common Stock — 5,894 shares (Direct)
Footnotes (13)
- F1. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F2. 794 restricted stock units vest on 5/1/2026 and 5/1/2027.
- F3. 600 restricted stock units vest on each of 6/2/2026, 6/2/2027 and 6/2/2028.
- F4. 1,379 restricted stock units vest on 8/15/2026.
- F5. 1,868 restricted stock units vest on 8/15/2026 and 1,869 restricted stock units vest on 8/15/2027.
- F6. 2,176 restricted stock units vest on each of 8/15/2026 and 8/15/2028; and 2,177 restricted stock units vest on 8/15/2027.
- F7. 100% vested.
- F8. Options to purchase 6,140 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.
- F9. Options to purchase 3,162 shares vest on each of 8/15/2024, 8/15/2026 and 8/15/2027; and options to purchase 3,163 shares vest on 8/15/2025.
- F10. Options to purchase 1,832 shares vest on each of 5/1/2025, 5/1/2026 and 5/1/2028; and options to purchase 1,831 shares vest on 5/1/2027.
- F11. Options to purchase 4,283 shares vest on each of 8/15/2025, 8/15/2027 and 8/15/2028; and options to purchase 4,284 shares vest on 8/15/2026.
- F12. Options to purchase 1,359 shares vest on each of 6/2/2026 and 6/2/2028; and options to purchase 1,358 shares vest on each of 6/2/2027 and 6/2/2029.
- F13. Options to purchase 4,788 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2029; and options to purchase 4,787 shares vest on 8/15/2028.
FAQ
What does the BIO-TECHNE (TECH) Form 3 for Steven C. Crouse report?
The Form 3 reports Steven C. Crouse’s existing equity holdings in BIO-TECHNE, including restricted stock units, stock options and common stock. It establishes his baseline ownership as an officer, detailing positions and vesting schedules rather than showing any new stock purchases or sales.
What restricted stock unit holdings are disclosed for BIO-TECHNE (TECH) executive Steven C. Crouse?
The Form 3 shows several restricted stock unit awards, including a position of 6,529 restricted stock units. Footnotes explain that each restricted stock unit equals one share of BIO-TECHNE common stock, with different grants vesting on specified dates between 2025 and 2028.
How do the stock options reported in BIO-TECHNE (TECH) Form 3 vest for Steven C. Crouse?
The filing lists multiple stock option grants with distinct vesting schedules from 2023 through 2029. Footnotes describe option tranches, such as options to purchase 6,140 shares vesting on each of August 15, 2023, 2024, 2025 and 2026, plus additional multi-year grants.
Does the BIO-TECHNE (TECH) Form 3 for Steven C. Crouse show any stock purchases or sales?
The Form 3 does not show any new stock purchases or sales. All transactions are coded as holdings, with transaction direction marked unknown. The document simply records existing restricted stock units, stock options and common shares along with their vesting schedules.
What vesting dates are highlighted for BIO-TECHNE (TECH) restricted stock units in this Form 3?
Footnotes highlight several vesting dates, including May 1, 2026 and 2027, June 2, 2026–2028, and August 15, 2026–2028. These dates apply to different restricted stock unit grants, specifying when Crouse becomes entitled to receive BIO-TECHNE common shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
